Join

Compare · MXCT vs PPD

MXCT vs PPD

Side-by-side comparison of MaxCyte Inc. (MXCT) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MXCT and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • PPD is the larger of the two at $16.64B, about 136.2x MXCT ($122.1M).
  • MXCT has hit the wire 1 time in the past 4 weeks while PPD has been quiet.
  • MXCT has more recent analyst coverage (11 ratings vs 1 for PPD).
MetricMXCTPPD
Company
MaxCyte Inc.
PPD, Inc.
Price
$1.13-2.16%
$47.29-0.07%
Market cap
$122.1M
$16.64B
1M return
+7.62%
-
1Y return
-47.44%
-
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NASDAQ
NASDAQ
IPO
2021
2020
News (4w)
1
0
Recent ratings
11
1
MXCT

MaxCyte Inc.

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

PPD

PPD, Inc.

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Latest MXCT

Latest PPD